Back to top

cell-therapy: Archive

Zacks Equity Research

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

ALNYPositive Net Change PFEPositive Net Change GILDPositive Net Change TARAPositive Net Change